Dewpoint Therapeutics nets $150m Series C

Dewpoint Therapeutics Inc, a biomolecular condensates company, has closed $150 million in Series C financing.

Dewpoint Therapeutics Inc, a biomolecular condensates company, has closed $150 million in Series C financing. SoftBank Vision Fund 2 led the round.

Source: Press Release